Abstract
AbstractThe high mortality and morbidity resulting from an increasing incidence of antibiotic resistance among pathogens highlight a crucial need for the development of novel alternative therapy. In the quest for alternative therapy, this study was conducted to synthesise nanoparticles (NPs) from ferric chloride hexahydrate (FeCl3.6H2O) via Melia azedarach L. (Meliaceae) leaf extract and evaluate their antibacterial properties against multidrug resistant pathogenic Escherichia coli, Salmonella enterica, and Vibrio cholerae. Multidrug-resistant pathogenic bacteria were isolated from cattle faeces and characterised by whole genome sequence analysis. The extracts from M. azedarach leaves were used as reducing, capping, and stabilising agents on the precursor metal (FeCl3.6H2O) to produce NPs. The biosynthesised NPs were characterised by ultraviolent visible (UV–vis) spectroscopy, X-ray diffraction (XRD), Fourier transform infrared spectrophotometry (FTIR), scanning electron microscopy (SEM), and transmission electron microscopy (TEM). The NPs were tested against multidrug-resistant bacteria to determine the minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and rate of kill. In this study, WGS analysis confirmed the bacteria (E. coli, V. cholerae, and S. enterica) isolates to be multidrug-resistant pathogen and NP that has a spherical shape with an average particle size of 49.75 nm was successfully biosynthesised. The NPs displayed significant antimicrobial activities with MIC of 62, 31, and 62 mg/mL, MBC of 500, 250, and 500 µg/mL, and the lowest killing times of 4, 2, and 3 h against E. coli, V. cholerae, and S. enterica, respectively. Interestingly, the concentrations of the NPs required to inhibit the growth of E. coli, V. cholerae, and S. enterica were not toxic to HEK293 cells. Based on the promising antimicrobial activities of the biosynthesised NPs in this study, they could be useful in important therapeutic applications aimed at combating multidrug-resistant pathogens.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.